Anti–IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison - Journal of Allergy and Clinical Immunology
FDA Will Review Teva's BLA for Asthma Drug Reslizumab
Israeli Pharma gets FDA Approval for Asthma Antibody
Safety of Reslizumab in Uncontrolled Asthma with Eosinophilia: A Pooled Analysis from 6 Trials - The Journal of Allergy and Clinical Immunology: In Practice
Teva's Asthma Segment: What Could Boost Its Revenues in 2016?
Teva files MAA for asthma treatment reslizumab
New Severe Asthma Rx Gets Green Light | RxWiki
Dosing and Administration
A Guide to the Prescription and Service Request Form
Brand name: Auvi-Q
BUY Reslizumab (CINQAIR) 10 mg/mL Teva Respiratory, LLC
Teva Announces EMA Validation of Reslizumab Marketing Authorization Application
Summary of ongoing reslizumab studies in patients with eosinophilic asthma. | Download Table
Clinical Outcomes and Health-Care Resource Use Associated With Reslizumab Treatment in Adults With Severe Eosinophilic Asthma in Real-World Practice - CHEST
Chest Medicine Made Easy-Dr Deepu: FDA approves Injectable drug for uncontrolled Asthma
Subcutaneous Cinqair results add to Teva's troubles
Teva announces FDA approval for asthma injection, Cinqair | Pharmafile
A Guide to the PRESCRIPTION AND SERVICE REQUEST FORM FOR CINQAIR® ( reslizumab) Injection
Teva's severe eosinophilic asthma drug Cinqaero wins EU approval
Reslizumab | New Drug Approvals
Rx Item-Cinqair (Reslizumab) 10Mg/Ml Inj Sinle Use Vial 10Ml By Teva Respiratory
Reslizumab - wikidoc
Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study - The Journal of Allergy and Clinical Immunology: In Practice
